Cat. #161905
Calu-1 Cell Line
Cat. #: 161905
Availability: 8-10 weeks
Organism: Human
Tissue: Lung
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Jorgen Fogh, Germain Trempe
Institute: Memorial Sloan-Kettering Cancer Center (MSK)
Primary Citation: Fogh J et al.1977.Journal of the National Cancer Institute. 59: 221-226.PMID: 327080.
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Calu-1 Cell Line
- Cancer: Carcinoma
- Organism: Human
- Gender: Male
- Tissue: Lung
- Donor: 47-year-old white male patient with epidermoid carcinoma
- Morphology: Epithelial
- Growth properties: Adherent
- Products or characteristics of interest: Isoenzymes: AK-1, 1; ES-D, 1; G6PD, B; GLO-I, 1-2; Me-2, 1-2; PGM1, 1-2; PGM3, 1
- Description: Human Lung Squamous Cell Carcinoma Cell Line. Calu-1 is a cell line exhibiting epithelial morphology that was isolated from the lungs of a 47-year-old, White male patient with epidermoid carcinoma. This product has applications in cancer research and toxicology.
- Application: 3D cell culture; Cancer research; High-throughput screening; Toxicology studies
- Biosafety level: 1
Target Details
- Target: BAntigen expression: lood Type A; Rh+; HLA A10, A11, B15, Bw35
Applications
- Application: 3D cell culture; Cancer research; High-throughput screening; Toxicology studies
Handling
- Growth medium: McCoy's 5a Medium Modified supplemented with 10% FBS
- Temperature: 37° C
- Shipping conditions: Dry Ice
- Storage medium: Complete growth medium supplemented with 5% (v/v) DMSO
- Storage conditions: Vapor phase of liquid nitrogen. Storage at -70° C will result in loss of viability.
- Str profiling: Amelogenin: X;CSF1PO: 10;D13S317: 11,12;D16S539: 11;D5S818: 10,12;D7S820: 9,10;TH01: 9,9.3;TPOX: 8;vWA: 15,16;D3S1358: 17;D21S11: 28;D18S51: 14,17;Penta_E: 11;Penta_D: 9;D8S1179: 10;FGA: 20,21;D19S433: 13,15;D2S1338: 16,17
References
- Fogh J et al.1977.Journal of the National Cancer Institute. 59: 221-226.PMID: 327080.
- Cavazzoni A et al. 2007. Cancer Letters. 246: 69-81. PMID: 16616810.
